Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. BioInvent International AB's annualized net income for the quarter that ended in Mar. 2026 was $-51.18 Mil. BioInvent International AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $53.57 Mil. Therefore, BioInvent International AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -95.55%.
The historical rank and industry rank for BioInvent International AB's Return-on-Tangible-Equity or its related term are showing as below:
BOVNF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -113.07 Med: -42.62 Max: -2.86
Current: -51.35
During the past 13 years, BioInvent International AB's highest Return-on-Tangible-Equity was -2.86%. The lowest was -113.07%. And the median was -42.62%.
BOVNF's Return-on-Tangible-Equity is ranked worse than 54.63% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs BOVNF: -51.35
BioInvent International AB (OTCPK:BOVNF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
BioInvent International AB Return-on-Tangible-Equity Related Terms
BioInvent International AB Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioInvent International AB Return-on-Tangible-Equity Chart
BOVNF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, BioInvent International AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioInvent International AB Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioInvent International AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where BioInvent International AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -95.55% mean?
BioInvent International AB (BOVNF) has a Return-on-Tangible-Equity of -95.55% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BioInvent International AB and its competitors. According to the industry distribution chart, BioInvent International AB ranks #655 out of 1199 companies in the Biotechnology industry, placing it in the top 54.6%.
Is BioInvent International AB's Return-on-Tangible-Equity too high?
BioInvent International AB's current Return-on-Tangible-Equity is -95.55%. Based on the distribution chart, BioInvent International AB ranks #655 out of 1199 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioInvent International AB has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does BioInvent International AB's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioInvent International AB ranks #655 out of 1199 companies for Return-on-Tangible-Equity. This places BioInvent International AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BioInvent International AB and its competitors. BioInvent International AB's current Return-on-Tangible-Equity is -95.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioInvent International AB stock overvalued right now?
BioInvent International AB (BOVNF) has a current Return-on-Tangible-Equity of -95.55%. The stock's GF Value™ is $6.77, compared to a current price of $3.29 — trading 51.4% below its estimated fair value. The current Return-on-Tangible-Equity is -95.55%. BioInvent International AB's overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For BioInvent International AB (BOVNF), the current Return-on-Tangible-Equity is -95.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioInvent International AB (BOVNF) Overvalued in 2026?
Based on GuruFocus' analysis, BioInvent International AB stock appears to be undervalued.
The current stock price of $3.29 is trading 51.4% below its estimated GF Value™ of $6.77.
Key valuation signals for BOVNF:
Return-on-Tangible-Equity: -95.55%
GF Value™: $6.77 vs. price of $3.29 (51.4% below fair value)
No single metric tells the full story. See the BOVNF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
50GF Score
Get the complete analysis for BOVNF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOVNF has been successfully added to your 
